CMNDNasdaqPharmaceutical PreparationsFiscal year ends October 31

Clearmind Medicine Inc.

Financials through Q3 FY2026, quarter ended Jul 31, 2026

$6.00−0.26 (-4.15%)

Close on Oct 19, 2026

Market cap: $9.49M
P/E (TTM): –
Dividend yield: –

Clearmind Medicine Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q3 2026 2026-07-31	TTM Q2 2026 2026-04-30	TTM Q1 2026 2026-01-31	TTM FY 2025 2025-10-31	TTM Q3 2025 2025-07-31	TTM Q2 2025 2025-04-30	TTM Q1 2025 2025-01-31	TTM FY 2024 2024-10-31	TTM Q3 2024 2024-07-31	TTM Q2 2024 2024-04-30	TTM Q1 2024 2024-01-31	TTM FY 2023 2023-10-31
Stock-Based Compensation	–	–	1.84	0.81	0.99	1.29	1.35	1.00	1.21	0.91	0.67	0.83
Change in Accounts Payable	0.00	0.17	0.19	0.08	0.30	0.01	0.15	-0.20	-0.10	-0.47	-0.31	-0.62
Operating Cash Flow	-7.07	-6.22	-5.55	-4.73	-4.53	-4.57	-4.66	-4.86	-4.53	-4.78	-4.66	-6.30
Investing Cash Flow	–	–	–	-0.54	-0.37	-0.45	–	-0.24	–	–	–	-0.03
Stock Issued	–	–	–	–	–	–	–	0.08	–	–	–	–
Financing Cash Flow	18	14	9.63	2.62	0.71	1.19	1.34	6.25	8.34	7.84	11	12
Foreign Exchange Rate Adjustments	-0.01	0.01	0.01	0.00	0.00	-0.01	-0.02	-0.01	-0.05	-0.04	-0.03	-0.04
Net Change in Cash	8.54	6.94	3.48	-2.65	-4.18	-3.83	-3.50	1.15	3.83	3.06	5.92	5.30

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 4.31
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 311.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –